- Human Cell Atlas Will Be ‘Google Maps’ for Health Research
- U.S. Postpartum Depression Diagnoses Doubled in a Decade
- California Child Tests Positive for Bird Flu
- About 1 in 10 U.S. Adults Have High Cholesterol
- Four Million Americans Could Lose Health Coverage Once ACA Credits Expire
- Child-Teacher Bond in Early Education Could Have Lasting Impact
- Surgeon General Says U.S. Smoking Rates Have Tumbled, But Not for Everyone
- Earlier Type 2 Diabetes Diagnoses Bring Higher Odds for Dementia
- A-fib Plus Heart Failure a Dangerous Combo
- Psychologists’ Group Issues First Guidance to Parents on Teen Online Video Use
Eli Lilly to Slash Insulin Prices, Cap Monthly Out-of-Pocket Costs at $35
More Americans will soon be paying less for their insulin.
Eli Lilly, one of the three insulin manufacturers, plans to cut its list prices of the drug by 70% and cap out-of-pocket costs at $35 a month.
“While the current health care system provides access to insulin for most people with diabetes, it still does not provide affordable insulin for everyone, and that needs to change,” Eli Lilly CEO David Ricks said in a company statement.
“The aggressive price cuts we’re announcing today should make a real difference for Americans with diabetes. Because these price cuts will take time for the insurance and pharmacy system to implement, we are taking the additional step to immediately cap out-of-pocket costs for patients who use Lilly insulin and are not covered by the recent Medicare Part D cap [on insulin costs],” Ricks added.
The company will cut its list price for Humalog 100 units/mL starting in the fourth quarter of 2023.
It will also cut its list price on non-branded Insulin Lispro Injection 100 units/mL, to $25 a vial. That cut will begin May 1, CBS News reported.
People with insurance will have a cap of $35 on out-of-pocket costs when buying the medication at participating retail pharmacies, the company said.
Those without insurance can also pay just $35 a month by downloading the company’s Insulin Value Program savings card.
That brings the costs in line with enrollees in Medicare, who had prices capped by the Biden administration’s Inflation Reduction Act last year.
Eli Lilly, Novo Nordisk and Sanofi are the three drugmakers that control the insulin market in the United States. About 3 in 10 people with diabetes use Eli Lilly’s insulin.
These drugmakers have been criticized for their high prices, up significantly since they began selling analog insulin products more than 20 years ago, CBS News reported. Some diabetics ration their medication, at great health risk, because of the high price of the medicine.
More information
The American Diabetes Association has more on diabetes.
SOURCES: Eli Lilly, news release, March 1, 2023; CBS News
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.
Related
-
-120x134.jpg)
More Hot Flashes Could Mean Higher Odds for Type 2 DiabetesMenopausal women with frequent hot flashes and night sweats...
- November 4, 2024
-
Late-Life Menopause Linked to Higher Asthma RiskWomen who enter menopause at a later age have...
- October 30, 2024
-
Biden Proposes That Insurers Cover Over-the-Counter Birth ControlHealth insurers would be required to cover the cost...
- October 21, 2024
-
Some IUDs May Raise The Odds for Breast Cancer, But Overall Risk Remains LowIntrauterine devices (IUDs) may raise the chances of a...
- October 18, 2024
-200x224.jpg)
